https://scholars.lib.ntu.edu.tw/handle/123456789/503485
DC 欄位 | 值 | 語言 |
---|---|---|
dc.contributor.author | Huang S.-H. | en_US |
dc.contributor.author | SHU-WEN LIN | en_US |
dc.contributor.author | SUI-YUAN CHANG | en_US |
dc.contributor.author | Lin Y.-T. | en_US |
dc.contributor.author | Chiang C. | en_US |
dc.contributor.author | Hsiao C.-F. | en_US |
dc.contributor.author | HSIN-YUN SUN | en_US |
dc.contributor.author | Liu W.-C. | en_US |
dc.contributor.author | Su Y.-C. | en_US |
dc.contributor.author | CHIEN-CHING HUNG | en_US |
dc.contributor.author | SHAN-CHWEN CHANG | en_US |
dc.creator | Huang S.-H.;Lin S.-W.;Sui-Yuan Chang;Lin Y.-T.;Chiang C.;Hsiao C.-F.;Sun H.-Y.;Liu W.-C.;Su Y.-C.;Hung C.-C.;Chang S.-C. | - |
dc.date.accessioned | 2020-06-18T08:25:54Z | - |
dc.date.available | 2020-06-18T08:25:54Z | - |
dc.date.issued | 2017 | - |
dc.identifier.issn | 2045-2322 | - |
dc.identifier.uri | https://scholars.lib.ntu.edu.tw/handle/123456789/503485 | - |
dc.description.abstract | We investigated the predictors of plasma mid-dose concentrations (C12) of efavirenz by enrolling 456 HIV-positive patients who had received 2 nucleos(t)ide reverse-transcriptase inhibitors plus efavirenz (600 mg daily) for 2 weeks or longer and had their CYP2B6 516G>T polymorphism and efavirenz C12 determined. The median efavirenz C12 was 2.41 mg/L (IQR, 1.93-3.14). In analysis of covariance models, patients with CYP2B6 516GT and TT genotypes compared to those with GG genotype had higher efavirenz C12 (for GT genotype, an increase by 0.976 mg/L [95%CI, 0.765-1.188], and TT genotype, 4.871 mg/L [95%CI, 4.126-5.616]), while per 10-kg increment in weight decreased C12 by 0.199 mg/L (95%CI, 0.111-0.287). Models incorporating CYP2B6 516G>T polymorphism and weight had moderate predictive values in predicting efavirenz C12 ? 2 mg/L (ROC area under curve = 0.706 [95%CI, 0.656-0.756]). In the absence of CYP2B6 516G>T polymorphism, weight ?58 kg provided better predictabilities for efavirenz C12 ? 2 mg/L (probability, 77.1% [95%CI, 69.0-83.5%] for weight = 50 kg and 70.6% [95%CI, 64.1-76.4%] for weight = 58 kg). ? 2017 The Author(s). | - |
dc.relation.ispartof | Scientific Reports | - |
dc.subject.classification | [SDGs]SDG3 | - |
dc.subject.other | antiretrovirus agent; benzoxazine derivative; cytochrome P450 2B6; efavirenz; adult; blood; female; genetics; genotype; human; Human immunodeficiency virus infection; male; single nucleotide polymorphism; young adult; Adult; Anti-Retroviral Agents; Benzoxazines; Cytochrome P-450 CYP2B6; Female; Genotype; HIV Infections; HIV Seropositivity; Humans; Male; Polymorphism, Single Nucleotide; Young Adult | - |
dc.title | Prediction of plasma efavirenz concentrations among HIV-positive patients taking efavirenz-containing combination antiretroviral therapy | en_US |
dc.type | journal article | en |
dc.identifier.doi | 10.1038/s41598-017-16483-2 | - |
dc.identifier.pmid | 29170492 | - |
dc.identifier.scopus | 2-s2.0-85034855984 | - |
dc.relation.pages | 16187 | - |
dc.relation.journalvolume | 7 | - |
dc.relation.journalissue | 1 | - |
item.cerifentitytype | Publications | - |
item.fulltext | no fulltext | - |
item.openairecristype | http://purl.org/coar/resource_type/c_6501 | - |
item.openairetype | journal article | - |
item.grantfulltext | none | - |
crisitem.author.dept | Clinical Pharmacy | - |
crisitem.author.dept | Pharmacy | - |
crisitem.author.dept | School of Pharmacy | - |
crisitem.author.dept | Pharmacy-NTUCC | - |
crisitem.author.dept | Clinical Laboratory Sciences and Medical Biotechnology | - |
crisitem.author.dept | Laboratory Medicine-NTUH | - |
crisitem.author.dept | Internal Medicine-NTUH | - |
crisitem.author.dept | Internal Medicine | - |
crisitem.author.dept | Internal Medicine | - |
crisitem.author.dept | Tropical Medicine and Parasitology | - |
crisitem.author.dept | Internal Medicine-NTUH | - |
crisitem.author.dept | Internal Medicine | - |
crisitem.author.dept | Internal Medicine-NTUH | - |
crisitem.author.dept | Office of the Vice President | - |
crisitem.author.dept | Clinical Pharmacy | - |
crisitem.author.dept | Medical Education and Bioethics | - |
crisitem.author.orcid | 0000-0002-9940-0850 | - |
crisitem.author.orcid | 0000-0002-6009-6724 | - |
crisitem.author.orcid | 0000-0003-0074-7721 | - |
crisitem.author.orcid | 0000-0001-7345-0836 | - |
crisitem.author.orcid | 0000-0001-6505-4139 | - |
crisitem.author.parentorg | College of Medicine | - |
crisitem.author.parentorg | College of Medicine | - |
crisitem.author.parentorg | College of Medicine | - |
crisitem.author.parentorg | National Taiwan University Cancer Center (NTUCC) | - |
crisitem.author.parentorg | College of Medicine | - |
crisitem.author.parentorg | National Taiwan University Hospital | - |
crisitem.author.parentorg | National Taiwan University Hospital | - |
crisitem.author.parentorg | College of Medicine | - |
crisitem.author.parentorg | College of Medicine | - |
crisitem.author.parentorg | College of Medicine | - |
crisitem.author.parentorg | National Taiwan University Hospital | - |
crisitem.author.parentorg | College of Medicine | - |
crisitem.author.parentorg | National Taiwan University Hospital | - |
crisitem.author.parentorg | Administrative Unit | - |
crisitem.author.parentorg | College of Medicine | - |
crisitem.author.parentorg | College of Medicine | - |
顯示於: | 醫學檢驗暨生物技術學系 |
在 IR 系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。